Search

Displaying results 2721 - 2730 of 10000 in total
  1. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    Detomidine is an α2-adrenergic agonist that is used as a horse sedative. Normally, it is administered in the salt form, detomidine hydrochloride. … This drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.

  2. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was first approved in Japan on 25 March 2013.

    Categories: Adenosine A2 Receptor Antagonists
  3. Drug

    Ubenimex

    go.drugbank.com/drugs/DB03424
    Investigational

    Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N.

  4. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging

  5. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). … It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.

  6. Drug

    Sulfoxone

    go.drugbank.com/drugs/DB01145
    Approved

    Sulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.

  7. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation

    Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Tribulus terrestris

    go.drugbank.com/drugs/DB14358
    Investigational

    Tribulus terrestris is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Medi DP Energy Bar
  9. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

  10. Drug

    Human immunoglobulin G

    go.drugbank.com/drugs/DB00028
    ApprovedInvestigational

    IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.

    Products: Gammagard S/d, Gamastan S/d